This connection further underscores the potential for targeting KCa3.1 as a therapeutic strategy for atherosclerosis, as improving mitochondrial function and activating PPAR pathways could collectively reduce vascular inflammation, improve plaque stability, and limit disease progression. The gene discussed is KCNN4; the disease is atherosclerosis.